zabmedvestnikЗабайкальский медицинский вестникTransbaikalian Medical Bulletin1998-6173Читинская государственная медицинская академия10.52485/19986173_2022_2_79zabmedvestnik-162Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSСОВРЕМЕННЫЙ ВЗГЛЯД НА МОРФОЛОГИЮ ПОРАЖЕНИЯ КОРОНАРНЫХ АРТЕРИЙ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2 ТИПАA MODERN VIEW ON THE MORPHOLOGY OF CORONARY ARTERIAL LESION IN PATIENTS WITH TYPE 2 DIABETES MELLITUSРинчиноваТ. С.RinchinovaT. S.

672000, Чита, ул. Горького, 39а

Chita, 39А Gorky Str., 672000

СеребряковаО. В.SerebryakovaO. V.

672000, Чита, ул. Горького, 39а

Chita, 39А Gorky Str., 672000

ФёдороваА. П.FedorovaA. P.

672000, Чита, ул. Горького, 39а

Chita, 39А Gorky Str., 672000

Федеральное государственное бюджетное образовательное учреждение высшего образования «Читинская государственная медицинская академия» Минздрава РоссииРоссияChita State Medical AcademyRussian Federation202205082024027990Copyright © Ринчинова Т.С., Серебрякова О.В., Фёдорова А.П., 20242024Ринчинова Т.С., Серебрякова О.В., Фёдорова А.П.Rinchinova T.S., Serebryakova O.V., Fedorova A.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.zabmedvestnik.ru/jour/article/view/162

В обзоре литературы мы рассмотрели ряд исследований, опубликованных за последние 10 лет, с целью выявления особенностей развития коронарного атеросклероза у пациентов с сахарным диабетом 2 типа в сочетании с ишемической болезнью сердца. В эту статью включены возможные маркеры крови как предикторы поражения коронарных артерий. В обзоре обобщены материалы о патогенетических механизмах влияния сахарного диабета на особенности развитие атеросклероза коронарных артерий. Данные из статей о пациентах с сахарным диабетом 2 типа были обобщены и представлены описательно.

In a literature review, we reviewed a number of studies published over the past 10 years in order to identify the features of the development of coronary atherosclerosis in patients with type 2 diabetes mellitus in combination with coronary heart disease. This article includes possible blood markers as predictors of coronary artery disease. The review summarizes materials on the pathogenetic mechanisms of the influence of diabetes mellitus on the features of the development of atherosclerosis of the coronary arteries. Data from articles on patients with type 2 diabetes were summarized and presented descriptively.

сердечно-сосудистые заболеваниякоронарный атеросклерозишемическая болезнь сердцасахарный диабет 2 типаcardiovascular diseasecoronary atherosclerosiscoronary heart diseasetype 2 diabetes mellitusИсследование не имело финансовой поддержкиReferencesРоссийское кардиологическое общество. Национальное общество по изучению атеросклероза. Национальное общество по атеротромбозу. Клинические рекомендации: Стабильная ишемическая болезнь сердца. 2020. 9-45.Russian Society of Cardiology. National Society for the Study of Atherosclerosis. National Society for Atherothrombosis. Clinical guidelines: Stable ischemic heart disease. 2020. 9-45.Шляхто Е.В. Кардиология: национальное руководство, 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа. 2015. 32-50.Shlyakhto E.V. Cardiology: a national guide, 2nd ed., Revised. and additional Moscow: GEOTAR-Media. 2015. 32-50.Кухарчук В.В., Коновалов Г.А., Сусеков А.В., и соавт. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Атеросклероз и дислипидемии. 2015. 2. 5-35.V. V. Kukharchuk, G. A. Konovalov, A. V. Susekov, et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. atherosclerosis and dyslipidemia. 2015. 2. 5-35.Карпов Ю.А., Кухарчук В.В., Лякишев А.А., Лупанов В.П., Панченко Е.П., Комаров А.Л., Ежов М.В., Ширяев А.А., Самко А.Н., Соболева Г.Н., Сорокин Е.В. Диагностика и лечение хронической ишемической болезни сердца (Практические рекомендации). Кардиологический вестник. 2015. 3. 3-33.Yu. A. Karpov, V. V. Kukharchuk, A. A. Lyakishev, V. P. Lupanov, E. P. Panchenko, A. L. Komarov, M. V. Ezhov, and A. A. Shiryaev, Samko A.N., Soboleva G.N., Sorokin E.V. Diagnosis and treatment of chronic coronary heart disease (Practical recommendations). Cardiology Bulletin. 2015. 3. 3-33.Серова Л.Д., Малыгина Н.А., Вершинин А.А., Мелентьев А.С., Костомарова И.В., Мелентьев И.А. Молекулярно-генетические маркеры для прогноза течения ишемической болезни сердца у больных старших возрастных групп. Российский кардиологический журнал. 2019. 4. 68-72.Serova L.D., Malygina N.A., Vershinin A.A., Melentiev A.S., Kostomarova I.V., Melentiev I.A. Molecular genetic markers for predicting the course of coronary heart disease in patients of older age groups. Russian journal of cardiology. 2019. 4. 68-72.Залесский В.Н., Гавриленко Т.И. Аутоиммунные и иммуновоспалительные процессы при атеросклерозе. 2017. 2. 5-9.Zalessky V.N., Gavrilenko T.I. Autoimmune and immunoinflammatory processes in atherosclerosis. 2017. 2. 5-9.Пузырев В.П., Степанов В.А., Макеева О.А. Синтропные гены болезней сердечно-сосудистого континуума. Вавиловский журнал генетики и селекции. 2019. 3. 31-38.Puzyrev V.P., Stepanov V.A., Makeeva O.A. Syntropic genes for diseases of the cardiovascular continuum. Vavilov Journal of Genetics and Breeding. 2019. 3. 31-38.International Diabetes Federation. International Diabetes Federation. 6th ed. IDF, Brussels. 2013. 100-125.International Diabetes Federation. International Diabetes Federation. 6th ed. IDF, Brussels. 2013. 100-125.Albers A.R., Krichavsky M.Z., Balady G.J. Stress testing in patients with diabetes mellitus. Circulation. 2016. 583–592.Albers A.R., Krichavsky M.Z., Balady G.J. Stress testing in patients with diabetes mellitus. circulation. 2016. 583–592. PMID: 16449735.Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest. 2015. 3378–3384.Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest. 2015. 3378–3384. PMID: 16322783.Lusis A.J. Atherosclerosis. Nature. 2000. 233–241.Lusis A.J. atherosclerosis. Nature. 2000. 233–241. PMID: 11001066.Hansson G.K., Robertson A.K., Sӧderberg Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2016. 297–329.Hansson G.K., Robertson A.K., Söderberg Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2016. 297–329. PMID: 18039117.Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011. 317–325.Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011. 317–325. PMID: 21593864.Norhammar A., Malmberg K., Diderholm E., et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2014. 585-591.Norhammar A., Malmberg K., Diderholm E., et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2014. 585-591.Dagenais G.R., Lu J., Faxon D.P., et al; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation. 2011. 1492-1500.Dagenais G.R., Lu J., Faxon D.P., et al; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation 2011. 1492-1500.Stone G.W., Rizvi A., Newman W., et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New Engl J Med 2010. 1663-1674.Stone G.W., Rizvi A., Newman W., et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New Engl J Med 2010. 1663-1674.Bangalore S., Kumar S., Fusaro M., et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 2012. 51-70.Bangalore S., Kumar S., Fusaro M., et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomized trials. BMJ 2012. 51-70.Kapur A., Hall R.J., Malik I.S., et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010. 432-440.Kapur A., Hall R.J., Malik I.S., et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010. 432-440.Mohr F.W., Morice M.C., Kappetein A.P., et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013. 629-638.Mohr F.W., Morice M.C., Kappetein A.P., et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013. 629-638.Mack M.J., Banning A.P., Serruys P.W., et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg 2011. 140-146.Mack M.J., Banning A.P., Serruys P.W., et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg 2011. 140-146.Farkouh M.E., Domanski M., Sleeper L.A., et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012. 375-384.Farkouh M.E., Domanski M., Sleeper L.A., et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012. 375-384.Rydén L., Grant P.J., Anker S.D., et al; ESC Committee for Practice Guidelines (CPG), Zamorano J.L., Achenbach S., Baumgartner H., et al; Document Reviewers, De Backer G, Sirnes P.A., Ezquerra E.A., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013. 35-87.Ryden L., Grant P.J., Anker S.D., et al; ESC Committee for Practice Guidelines (CPG), Zamorano J.L., Achenbach S., Baumgartner H., et al; Document Reviewers, De Backer G., Sirnes P.A., Ezquerra E.A., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013. 35-87.Baber U., Mehran R., Sharma S.K., et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011. 69-77.Baber U., Mehran R., Sharma S.K., et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011. 69-77.Stone G.W., Sabik J.F., Serruys P.W., Simonton C.A., et al; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 2016. 375. 23-35.Stone G.W., Sabik J.F., Serruys P.W., Simonton C.A., et al; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 2016. 375. 23-35.Bangalore S., Toklu B., Feit F. Outcomes With Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Patients With Diabetes Mellitus: Can Newer Generation Drug-Eluting Stents Bridge the Gap Circ Cardiovasc Interv 2014. 7. 518-525.Bangalore S., Toklu B., Feit F. Outcomes With Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary InterventiBalabanova R.M., Dubinina T.V., JerdesSh.F. The dynamics of the incidence of rheumatic diseases of the adult population of Russia in 2010-2014. Nauchno- prakticheskaja revmatologiya. 2016. 54 (3). 266-270. in Russian. DOI: 10.14412/1995-4484-2016-266-270.Park S.J., Ahn J.M., Kim Y.H., et al; BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015. 4-12.Park S.J., Ahn J.M., Kim Y.H., et al; BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015. 4-12.American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012. 35. 11- 63. (Review)American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012. 35. 11- 63. (Review)Smith S.C. Jr., Benjamin E.J., Bonow R.O., et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2017. 124. 58-73.Smith S.C. Jr, Benjamin E.J., Bonow R.O., et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2017. 124. 58-73.Sanchis Gomar F., Perez Quilis C., Leischik R., Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016. 4. 256.Sanchis Gomar F., Perez Quilis C., Leischik R., Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016. 4. 256. PMID: 27500157.Dev K., Sharma S.B., Garg S., Aggarwal A., Madhu S.V. Glycated apolipoprotein B-A surrogate marker of subclinical atherosclerosis. Diabetes Metab Syndr. 2016. 10. 78–81.Dev K., Sharma S.B., Garg S., Aggarwal A., Madhu S.V. Glycated apolipoprotein B-A surrogate marker of subclinical atherosclerosis. Diabetes Metab Syndr. 2016. 10. 78–81. PMID: 26614298.Patsouras A., Farmaki P., Garmpi A., Damaskos C., Garmpis N., Mantas D., Diamantis E. Screening and Risk Assessment of Coronary Artery Disease in Patients With Type 2 Diabetes: An Updated Review. In Vivo. 2019 Jul-Aug. 33(4). 1039-1049.Patsouras A., Farmaki P., Garmpi A., Damaskos C., Garmpis N., Mantas D., Diamantis E. Screening and Risk Assessment of Coronary Artery Disease in Patients With Type 2 Diabetes: An Updated Review. In Vivo. 2019 Jul-Aug;33(4):1039-1049.Chen J., Zhang Y., Liu J., Chen M.H., Guo Y.L., Zhu C.G., Xu R.X., Dong Q., Li J.J. Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation. Diabetes Vasc Dis Res. 2015. 12. 258–264.Chen J., Zhang Y., Liu J., Chen M.H., Guo Y.L., Zhu C.G., Xu R.X., Dong Q., Li J.J. Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation. Diabetes Vasc Dis Res. 2015. 12. 258–264. PMID: 25861813.Gouni-Berthold I., Berthold H.K. Lipoprotein(a): current perspectives. Curr Vasc Pharmacol. 2011. 9. 682–692.Gouni-Berthold I., Berthold H.K. Lipoprotein(a): current perspectives. Curr Vasc Pharmacol. 2011. 9. 682–692. PMID: 21529331.Ozturk D., Celik O., Satilmis S., Aslan S., Erturk M., Cakmak H.A., Kalkan A.K., Ozyilmaz S., Diker V., Gul M. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis. 2015. 26. 396–401.Ozturk D., Celik O., Satilmis S., Aslan S., Erturk M., Cakmak H.A., Kalkan A.K., Ozyilmaz S., Diker V., Gul M. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis. 2015. 26. 396–401. PMID: 25887000.Srinivasan M.P., Kamath P.K., Bhat N.M., Pai N.D., Manjrekar P.A., Mahabala C. Factors associated with no apparent coronary artery disease in patients with type 2 diabetes mellitus for more than 10 years of duration: A case control study. Cardiovasc Diabetol. 2015.14.146–152.Srinivasan M.P., Kamath P.K., Bhat N.M., Pai N.D., Manjrekar P.A., Mahabala C. Factors associated with no apparent coronary artery disease in patients with type 2 diabetes mellitus for more than 10 years of duration: A case control study. Cardiovasc Diabetol. 2015.14.146–152. PMID: 26521236.Tasevska I., Enhörning S., Persson M., Nilsson P.M., Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart. 2016. 102. 127–132.Tasevska I., Enhörning S., Persson M., Nilsson P.M., Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart. 2016. 102. 127–132. PMID: 26661323.Enhorning S., Wang T.J., Nilsson P.M., Almgren P., Hedblad B., Berglund G., Struck J., Morgenthaler N.G., Bergmann A., Lindholm E., Groop L., Lyssenko V., Orho Melander M., Newton Cheh C., Melander O. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010. 121. 2102–2108.Enhorning S., Wang T.J., Nilsson P.M., Almgren P., Hedblad B., Berglund G., Struck J., Morgenthaler N.G., Bergmann A., Lindholm E., Groop L., Lyssenko V., Orho Melander M., Newton Cheh C., Melander O. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010. 121. 2102–2108. PMID: 20439785.Abbasi A., Corpeleijn E., Meijer E., Postmus D., Gansevoort R.T., Gans R.O., Struck J., Hillege H.L., Stolk R.P., Navis G., Bakker S.J. Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012. 55. 1963–1970.Abbasi A., Corpeleijn E., Meijer E., Postmus D., Gansevoort R.T., Gans R.O., Struck J., Hillege H.L., Stolk R.P., Navis G., Bakker S.J. Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012. 55. 1963–1970. PMID: 22526609.Paul Chubb S.A., Davis W.A., Peters K.E., Davis T.M. Serum bicarbonate concentration and the risk of cardiovascular disease and death in type 2 diabetes: the Fremantle Diabetes Study. Cardiovasc Diabetol. 2016. 15. 143–143.Paul Chubb S.A., Davis W.A., Peters K.E., Davis T.M. Serum bicarbonate concentration and the risk of cardiovascular disease and death in type 2 diabetes: the Fremantle Diabetes Study. Cardiovasc Diabetol. 2016. 15. 143–143. PMID: 27716263.Hao F., Zhang H.J., Zhu J., Kuang H., Yu Q., Bai M., Mu J. Association between vaspin level and coronary artery disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2016. 113. 26–32.Hao F., Zhang H.J., Zhu J., Kuang H., Yu Q., Bai M., Mu J. Association between vaspin level and coronary artery disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2016. 113.26–32. PMID: 26972957.Adela R., Banerjee S.K. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res. 2015. 490842. DOI: 10.1155/2015/490842.Adela R., Banerjee S.K. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res. 2015;2015:490842. DOI: 10.1155/2015/490842. Epub 2015 Jul 27. PMID: 26273671.Aust G., Richter O., Rohm S., Kerner C., Hauss J., Klöting N., Ruschke K., Kovacs P., Youn B.S., Blüher M. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009. 204. 262–266.Aust G., Richter O., Rohm S., Kerner C., Hauss J., Klöting N., Ruschke K., Kovacs P., Youn B.S., Blüher M. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009. 204. 262–266. PMID: 18848328.Jung C.H., Lee W.J., Hwang J.Y., Seol S.M., Kim Y.M., Lee Y.L., Park J.Y. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3- kinase/Akt pathway. Biochem Biophys Res Commun. 2011. 413. 264–269.Jung C.H., Lee W.J., Hwang J.Y., Seol S.M., Kim Y.M., Lee Y.L., Park J.Y. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3- kinase/Akt pathway. Biochem Biophys Res Commun. 2011. 413. 264–269. PMID: 21893030.Nakatsuka A., Wada J., Iseda I., Teshigawara S., Higashio K., Murakami K., Kanzaki M., Inoue K., Terami T., Katayama A., Hida K., Eguchi J., Ogawa D., Matsuki Y., Hiramatsu R., Yagita H., Kakuta S., Iwakura Y., Makino H. Vaspin inhibits apoptosis of endothelial cells as a ligand for cell-surface GRP78/VDAC complex. Circ Res. 2013. 112. 771–780.Nakatsuka A., Wada J., Iseda I., Teshigawara S., Higashio K., Murakami K., Kanzaki M., Inoue K., Terami T., Katayama A., Hida K., Eguchi J., Ogawa D., Matsuki Y, Hiramatsu R., Yagita H., Kakuta S., Iwakura Y., Makino H. Vaspin inhibits apoptosis of endothelial cells as a ligand for cell-surface GRP78/VDAC complex. Circ Res. 2013. 112..771–780. PMID: 23307819.Müller K.A., Rath D., Schmid M., Schoenleber H., Gawaz M., Geisler T., Müller I.I. High plasma levels of gremlin-1 and macrophage migration inhibitory factor, but not their ratio, indicate an increased risk for acute coronary syndrome in patients with type 2 diabetes mellitus. Clin Cardiol. 2016. 39.201–206.Müller K.A., Rath D., Schmid M., Schoenleber H., Gawaz M., Geisler T., Müller I.I. High plasma levels of gremlin-1 and macrophage migration inhibitory factor, but not their ratio, indicate an increased risk for acute coronary syndrome in patients with type 2 diabetes mellitus. Clin Cardiol. 2016. 39.201–206. PMID: 27101443.Müller I.I., Müller K.A., Karathanos A., Schönleber H., Rath D., Vogel S., Chatterjee M., Schmid M., Haas M., Seizer P., Langer H., Schaeffeler E., Schwab M., Gawaz M., Geisler T. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. Atherosclerosis. 2014. 237. 426–432.Müller I.I., Müller K.A., Karathanos A., Schönleber H., Rath D., Vogel S., Chatterjee M., Schmid M., Haas M., Seizer P., Langer H., Schaeffeler E., Schwab M., Gawaz M., Geisler T. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. Atherosclerosis. 2014. 237.426–432. PMID: 25463068.Valensi P., Avignon A., Sultan A., Chanu B., Nguyen M.T., Cosson E. Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross sectional study. Cardiovasc Diabetol. 2016. 15. 104–113.Valensi P., Avignon A., Sultan A., Chanu B., Nguyen M.T., Cosson E. Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross sectional study. Cardiovasc Diabetol. 2016. 15. 104–113. PMID: 27450534.

The authors declare that there are no conflicts of interest present.